SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) "

Sökning: hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin)

  • Resultat 109771-109780 av 139652
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
109771.
  • Hjorth, Erik, et al. (författare)
  • Immunomodulation of microglia by docosahexaenoic acid and eicosapentaenoic acid.
  • 2012
  • Ingår i: Current opinion in clinical nutrition and metabolic care. - : Lippincott Williams & Wilkins. - 1363-1950 .- 1473-6519. ; 15:2, s. 134-143
  • Forskningsöversikt (refereegranskat)abstract
    • PURPOSE OF REVIEW: The omega-3 fatty acids (ω-3 FAs) docosahexaenoic acid and eicosapentaenoic acid are dietary components which have been ascribed many different health benefits. Inflammation is present in, and contributes to, pathological conditions in the central nervous system (CNS). Microglia are the primary cells with immune function in the CNS, and inflammation mediated by activated microglia is present in pathological conditions. In this review, we present and discuss findings on the modulation of microglial activities by ω-3 FAs in vivo as well as in vitro, and propose mechanisms for their effects.RECENT FINDINGS: The majority of studies show that ω-3 FAs have anti-inflammatory effects on microglia. However, phagocytosis is an activity associated with inflammation and is increased by ω-3 FAs. This can be understood in the light of recent research on the resolution of inflammation. Resolution is induced by proresolving factors, which are metabolites of ω-3 FAs. Proresolving factors are anti-inflammatory and have been shown to increase phagocytosis. Other mechanisms of the anti-inflammatory actions of ω-3 FAs involve the peroxisome proliferator-activated receptor-γ, ω-3 FA incorporation into the cell membrane, and inhibition of ion currents.SUMMARY: Immunomodulation by ω-3 FAs is mediated by several pathways that are interconnected and is a potential therapy for disorders in the CNS.
  •  
109772.
  • Hjorth, Lars, et al. (författare)
  • Survivorship after childhood cancer: PanCare: A European Network to promote optimal long-term care.
  • 2015
  • Ingår i: European Journal of Cancer. - : Elsevier BV. - 1879-0852 .- 0959-8049. ; 51:10, s. 1203-1211
  • Tidskriftsartikel (refereegranskat)abstract
    • Survival after childhood cancer has improved substantially over recent decades. Although cancer in childhood is rare increasingly effective treatments have led to a growing number of long-term survivors. It is estimated that there are between 300,000 and 500,000 childhood cancer survivors in Europe. Such good survival prospects raise important questions relating to late effects of treatment for cancer. Research has shown that the majority will suffer adverse health outcomes and premature mortality compared with the general population. While chronic health conditions are common among childhood cancer survivors, each specific type of late effect is very rare. Long-term effects must be considered particularly when addressing complex multimodality treatments, and taking into account the interaction between aspects of treatment and genotype. The PanCare Network was set up across Europe in order to effectively answer many of these questions and thereby improve the care and quality of life of survivors. The need for a structured long-term follow-up system after childhood cancer has been recognised for some time and strategies for implementation have been developed, first nationally and then trans-nationally, across Europe. Since its first meeting in Lund in 2008, the goal of the PanCare Network has been to coordinate and implement these strategies to ensure that every European survivor of childhood and adolescent cancer receives optimal long-term care. This paper will outline the structure and work of the PanCare Network, including the results of several European surveys, the start of two EU-funded projects and interactions with relevant stakeholders and related projects.
  •  
109773.
  • Hjorth, Maria, et al. (författare)
  • GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.
  • 2011
  • Ingår i: Clinical Immunology. - : Elsevier. - 1521-6616 .- 1521-7035. ; 138:1, s. 117-126
  • Tidskriftsartikel (refereegranskat)abstract
    • Type 1 diabetes results from autoimmune destruction of insulin producing pancreatic β-cells. We have shown that treatment with alum-formulated glutamic acid decarboxylase 65 (GAD-alum) preserved residual insulin secretion and induced antigen-specific responses in children with recent onset type 1 diabetes. The aim of this study was to further investigate the immunomodulatory effect of GAD-alum, focusing on CD4+CD25high cells and their association to cytokine secretion. Samples obtained 21 and 30 months after the initial injection of GAD-alum or placebo were included in the present study. GAD65-stimulation enhanced the percentage of CD4+CD25highFOXP3+ cells, but reduced the percentage of CD4+CD25+ cells, in samples from the GAD-alum treated group. Further, the GAD65-induced secretion of IL-5, -10, and -13 correlated with the expression of CD4+CD25highFOXP3+ cells, but inversely with CD4+CD25+ cells. These new data suggest that GAD-alum treatment induced GAD65-specific T cells with regulatory features.
  •  
109774.
  • Hjorth, Martin, et al. (författare)
  • Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
  • 2012
  • Ingår i: European journal of haematology. - : Wiley. - 0902-4441 .- 1600-0609. ; 88:6, s. 485-496
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
    • Objectives: Thalidomide and bortezomib have been frequently used for second-line therapy in patients with myeloma relapsing after or refractory to initial melphalan-based treatment, but no randomized trials have been published comparing these two treatment alternatives. Methods: Thalidomide- and bortezomib-naïve patients with melphalan refractory myeloma were randomly assigned to low-dose thalidomide + dexamethasone (Thal-Dex) or bortezomib + dexamethasone (Bort-Dex). At progression on either therapy, the patients were offered crossover to the alternative drug combination. An estimated 300 patients would be needed for the trial to detect a 50% difference in median PFS between the treatment arms. Results: After inclusion of 131 patients, the trial was prematurely closed because of low accrual. Sixty-seven patients were randomized to Thal-Dex and 64 to Bort-Dex. Progression-free survival was similar (median, 9.0 months for Thal-Dex and 7.2 for Bort-Dex). Response rate was similar (55% for Thal-Dex and 63% for Bort-Dex), but time to response was shorter (P < 0.05) and the VGPR rate higher (P < 0.01) for Bort-Dex. Time-to-other treatment after crossover was similar (median, 13.2 months for Thal-Dex and 11.2 months for Bort-Dex), as was overall survival (22.8 months for Thal-Dex and 19.0 for Bort-Dex). Venous thromboembolism was seen in seven patients and cerebrovascular events in four patients in the Thal-Dex group. Severe neuropathy, reactivation of herpes virus infections, and mental depression were more frequently observed in the Bort-Dex group. In the quality-of-life analysis, no difference was noted for physical function, pain, and global quality of life. Fatigue and sleep disturbances were significantly more prevalent in the Bort-Dex group. Conclusions: Thalidomide (50–100 mg daily) in combination with dexamethasone seems to have an efficacy comparable with that of bortezomib and dexamethasone in melphalan refractory myeloma. However, the statistical strength of the results in this study is limited by the low number of included patients.
  •  
109775.
  • Hjorth, Thérése, 1985, et al. (författare)
  • Sixteen-week multicentre randomised controlled trial to study the effect of the consumption of an oat beta-glucan-enriched bread versus a whole-grain wheat bread on glycaemic control among persons with pre-diabetes: a study protocol of the CarbHealth study
  • 2022
  • Ingår i: BMJ Open. - : BMJ. - 2044-6055 .- 2044-6055. ; 12:8, s. e062066-
  • Tidskriftsartikel (refereegranskat)abstract
    • INTRODUCTION: In 2012, the estimated global prevalence of pre-diabetes was 280 million, and the prevalence is expected to rise to 400 million by 2030. Oat-based foods are a good source of beta-glucans, which have been shown to lower postprandial blood glucose. Studies to evaluate the effectiveness of the long-term intake of beta-glucan-enriched bread as part of a habitual diet among individuals with pre-diabetes are needed. Therefore, we designed a multicentre intervention study in adults with pre-diabetes to investigate the effects of consumption of an oat-derived beta-glucan-enriched bread as part of a normal diet on glycated haemoglobin (HbA1c) in comparison to consumption of whole-grain wheat bread. METHODS AND ANALYSIS: The CarbHealth trial is a multicentre double-blind randomised controlled 16-week dietary intervention trial in participants 40-70 years of age with a body mass index of ≥27 kg/m2 and HbA1c of 35-50 mmol/mol. The study is conducted at four universities located in Norway, Sweden and Germany and uses intervention breads specifically designed for the trial by Nofima AS. The aim is to recruit 250 participants. The primary outcome is the difference in HbA1c between the intervention and the control groups. The main analysis will include intervention group, study centre and baseline HbA1c as independent variables in an analysis of covariance model. ETHICS AND DISSEMINATION: The study protocol was approved by respective ethical authorities in participating countries. The results of the study will be communicated through publication in international scientific journals and presentations at (inter)national conferences. TRIAL REGISTRATION NUMBER: NCT04994327.
  •  
109776.
  • Hjorton, Karin, et al. (författare)
  • Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor
  • 2018
  • Ingår i: Arthritis Research & Therapy. - : Springer Science and Business Media LLC. - 1478-6362. ; 20
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: In systemic lupus erythematosus (SLE), immune complexes (ICs) containing self-derived nucleic acids trigger the synthesis of proinflammatory cytokines by immune cells. We asked how an interleukin (IL)-1 receptor-associated kinase 4 small molecule inhibitor (IRAK4i) affects RNA-IC-induced cytokine production compared with hydroxychloroquine (HCQ).Methods: Plasmacytoid dendritic cells (pDCs) and natural killer (NK) cells were isolated from peripheral blood mononuclear cells (PBMCs) of healthy individuals. PBMCs from SLE patients and healthy individuals were depleted of monocytes. Cells were stimulated with RNA-containing IC (RNA-IC) in the presence or absence of IRAK4i I92 or HCQ, and cytokines were measured by immunoassay or flow cytometry. Transcriptome sequencing was performed on RNA-IC-stimulated pDCs from healthy individuals to assess the effect of IRAK4i and HCQ.Results: In healthy individuals, RNA-IC induced interferon (IFN)-α, tumor necrosis factor (TNF)-α, IL-6, IL-8, IFN-γ, macrophage inflammatory protein (MIP)1-α, and MIP1-β production in pDC and NK cell cocultures. IFN-α production was selective for pDCs, whereas both pDCs and NK cells produced TNF-α. IRAK4i reduced the pDC and NK cell-derived cytokine production by 74–95%. HCQ interfered with cytokine production in pDCs but not in NK cells. In monocyte-depleted PBMCs, IRAK4i blocked cytokine production more efficiently than HCQ. Following RNA-IC activation of pDCs, 975 differentially expressed genes were observed (false discovery rate (FDR) < 0.05), with many connected to cytokine pathways, cell regulation, and apoptosis. IRAK4i altered the expression of a larger number of RNA-IC-induced genes than did HCQ (492 versus 65 genes).Conclusions: The IRAK4i I92 exhibits a broader inhibitory effect than HCQ on proinflammatory pathways triggered by RNA-IC, suggesting IRAK4 inhibition as a therapeutic option in SLE.
  •  
109777.
  •  
109778.
  •  
109779.
  • Hjorton, Karin, 1974- (författare)
  • The activation and regulation of plasmacytoid dendritic cells in SLE : and possible therapeutic interventions
  • 2020
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • Systemic Lupus Erythematosus (SLE) is an autoimmune disease, characterized by the presence of anti-nuclear antibodies and the formation of nucleic acid containing immune complexes (ICs), which can cause organ damage by deposition in tissues. ICs strongly trigger the plasmacytoid dendritic cells (pDCs) to produce interferon (IFN)-α, which potently activates the immune system. An activated type I IFN system is seen in a majority of SLE patients. Natural killer (NK) cells enhance the IC triggered response of pDCs. Other NK cell alterations are described in SLE. Standard SLE treatment, hydroxychloroquine (HCQ), reduces flare risks, and HCQ concentration measurement can optimize its dosing. However, new treatments are needed.In paper I, we screened for autoantibodies to lectin-like NK cell receptors. In 3.4% of SLE patient sera, autoantibodies to CD94/NKG2A and CD94/NKG2C were found, which interfered with HLA-E mediated regulation of NK cell cytotoxicity, and facilitated elimination of target cells expressing expressing these receptors. Autoantibody levels correlated with SLE disease activity and with a more severe disease phenotype.In paper II, we found that RNA-IC triggered proinflammatory cytokine production in immune cells from healthy blood donors and SLE patients. After RNA-IC stimulation of pDCs, RNA sequencing detected 975 differentially expressed genes, connected to cytokine pathways, cell regulation and apoptosis. An IRAK4i had a broader inhibitory effect on RNA-IC triggered cytokine production and pro-inflammatory pathways than HCQ.In paper III we showed that RNA-IC induced type III IFN production in a subset of pDCs (3%) which also produced type I IFN. Type III IFN production by pDCs was enhanced by NK and B cells, as well as by IFN-λ2, IFN-α2b, interleukin (IL)-3, IL-6 and GM-CSF. Type III IFN production by RNA-IC stimulated immune cells of SLE patients was detected in a minority. IFN-α2b and GM-CSF increased the proportion of responders to RNA-IC from 11 to 33%.In paper IV a LC-HRMS method, was evaluated for HCQ concentration measurement in whole blood (WB), serum and plasma from 26 SLE patients. The levels in WB were approximately 2-fold compared to serum and plasma, and correlated with weekly HCQ-dose. Large inter-individual variations were observed, despite equal doses. The WB matrix showed superior reproducibility in patient samples (CV<5%).These findings add to the knowledge of how cytokine production by pDCs in SLE is regulated, and support a role for NK cells in the pathogenesis of SLE. Moreover WB was the superior matrix for HCQ measurement in SLE patients.
  •  
109780.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 109771-109780 av 139652
Typ av publikation
tidskriftsartikel (114393)
konferensbidrag (6861)
doktorsavhandling (6560)
forskningsöversikt (6147)
bokkapitel (2704)
annan publikation (1793)
visa fler...
rapport (460)
bok (311)
samlingsverk (redaktörskap) (140)
licentiatavhandling (116)
recension (72)
patent (57)
proceedings (redaktörskap) (37)
konstnärligt arbete (13)
visa färre...
Typ av innehåll
refereegranskat (117295)
övrigt vetenskapligt/konstnärligt (21579)
populärvet., debatt m.m. (756)
Författare/redaktör
Zetterberg, Henrik, ... (793)
Blennow, Kaj, 1958 (745)
Melander, Olle (650)
Larsson, Anders (619)
Gillberg, Christophe ... (619)
Sundquist, Kristina (597)
visa fler...
Sundquist, Jan (595)
Nilsson, Peter (580)
Groop, Leif (575)
Lundälv, Jörgen, 196 ... (570)
Janson, Christer (519)
Ohlsson, Claes, 1965 (513)
Larsson, Henrik, 197 ... (502)
Engström, Gunnar (472)
Lind, Lars (465)
Hansson, Oskar (458)
Riboli, Elio (451)
Tumino, Rosario (439)
Erlinge, David (433)
Overvad, Kim (414)
Kaaks, Rudolf (406)
Swedberg, Karl, 1944 (400)
Olsson, Håkan (399)
Rosengren, Annika, 1 ... (398)
Stattin, Pär (394)
Ludvigsson, Jonas F. ... (393)
Trichopoulou, Antoni ... (391)
Boeing, Heiner (390)
Wennergren, Göran, 1 ... (389)
Karlsson, Jón, 1953 (380)
Bruze, Magnus (373)
Andersson, Roland (368)
Stibrant Sunnerhagen ... (357)
Khaw, Kay-Tee (343)
Wolk, Alicja (342)
Simrén, Magnus, 1966 (336)
Weiderpass, Elisabet ... (336)
Forssell-Aronsson, E ... (334)
Palli, Domenico (333)
Herlitz, Johan, 1949 (331)
Lichtenstein, Paul (325)
Hemminki, Kari (325)
Glimelius, Bengt (323)
Jirström, Karin (315)
Norrving, Bo (312)
Borg, Åke (310)
Lernmark, Åke (306)
Manjer, Jonas (304)
Giwercman, Aleksande ... (304)
Jacobsson, Bo, 1960 (299)
visa färre...
Lärosäte
Lunds universitet (47568)
Göteborgs universitet (36559)
Uppsala universitet (27522)
Karolinska Institutet (26311)
Umeå universitet (16671)
Linköpings universitet (11843)
visa fler...
Örebro universitet (9596)
Malmö universitet (3422)
Stockholms universitet (2875)
Kungliga Tekniska Högskolan (2429)
Chalmers tekniska högskola (2060)
Jönköping University (1726)
Linnéuniversitetet (1172)
Högskolan Dalarna (1028)
Högskolan i Skövde (788)
Sveriges Lantbruksuniversitet (760)
Högskolan i Halmstad (716)
Mittuniversitetet (647)
Högskolan i Borås (610)
Högskolan Kristianstad (550)
Karlstads universitet (508)
Mälardalens universitet (504)
Sophiahemmet Högskola (437)
Luleå tekniska universitet (393)
Gymnastik- och idrottshögskolan (366)
Högskolan Väst (306)
Högskolan i Gävle (304)
Marie Cederschiöld högskola (292)
Röda Korsets Högskola (235)
Blekinge Tekniska Högskola (216)
RISE (190)
Södertörns högskola (130)
Handelshögskolan i Stockholm (98)
VTI - Statens väg- och transportforskningsinstitut (58)
Försvarshögskolan (12)
Naturhistoriska riksmuseet (9)
Konstfack (4)
IVL Svenska Miljöinstitutet (4)
Stockholms konstnärliga högskola (3)
Kungl. Musikhögskolan (3)
Nordiska Afrikainstitutet (2)
visa färre...
Språk
Engelska (133625)
Svenska (5490)
Tyska (154)
Danska (50)
Spanska (44)
Franska (38)
visa fler...
Norska (38)
Odefinierat språk (36)
Finska (35)
Ungerska (31)
Portugisiska (22)
Isländska (17)
Italienska (14)
Kinesiska (11)
Ryska (9)
Japanska (9)
Polska (6)
Tjeckiska (6)
Nederländska (5)
Nygrekiska (3)
Esperanto (2)
Bosniska (2)
Grekiska, klassisk (1)
Estniska (1)
Rumänska (1)
Ukrainska (1)
visa färre...
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (139638)
Samhällsvetenskap (3765)
Naturvetenskap (3379)
Teknik (1590)
Humaniora (589)
Lantbruksvetenskap (363)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy